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Genetic variants influencing 
effectiveness of weight loss strategies
Variantes genéticos influenciando a efetividade 
das estratégias de perda de peso
Sophie Deram1,2, Sandra M. F. Villares1,2
ABSTRACT
Body weight excess has an increasingly high prevalence in the world. Obesity is a complex 
disease of multifactorial origin with a polygenic condition affected by environmental factors. 
Weight loss is a primary strategy to treat obesity and its morbidities. Weight changes through 
life depend on the interaction of environmental, behavioral and genetic factors. Interindividual 
variation of weight loss in response to different types of interventions (behavioral, caloric res-
triction, exercise, drug or surgery) has been observed. In this article, currently available data 
on the role of candidate gene polymorphisms in weight loss are reviewed. Even though control 
of weight loss by genotype was described in twin and family studies, it is premature to recom-
mend use of genotyping in the design of therapeutic diets or drug treatment. Future studies 
will have to be large in order to assess the effects of multiple polymorphisms, and will have to 
control factors other than diet. Arq Bras Endocrinol Metab. 2009;53(2):129-138.
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RESUMO
A prevalência do excesso de peso cresce no mundo todo. De origem multifatorial, a obesidade é 
uma doença complexa, com condição poligênica afetada por fatores ambientais. A perda de peso 
é a estratégia primária utilizada para prevenir e tratar a obesidade bem como suas comorbidades. 
Mudanças de peso durante a vida dependem da interação entre fatores ambientais, comporta-
mentais e genéticos. Observa-se grande variação da perda de peso entre indivíduos em resposta 
a diferentes modelos de intervenções (comportamentais, restrições da ingesta cálorica, exercícios 
físicos, drogas antiobesidade ou cirurgias). Este artigo é uma revisão atual da literatura disponível, 
que busca abordar o papel dos polimorfismos dos genes candidatos à obesidade e sua influên cia 
na perda de peso. Apesar da interação do genótipo na perda de peso corporal, descrita nos estu-
dos de gêmeos e familiares, é prematuro recomendar o uso da genotipagem para estratégias de 
perda de peso. É necessário ampliar as pesquisas sobre os efeitos sinérgicos dos polimorfismos 
genéticos com coorte maior e associá-los não somente à restrição alimentar mas também às ou-
tras intervenções que auxiliam na perda de peso. Arq Bras Endocrinol Metab. 2009;53(2):129-138.
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INTRODUCTION 
Excess body weight is highly prevalent in most coun-tries and the rapid weight gain in the population 
is likely due to a changing environment (obesogenic 
environment and behavior), with a misbalance between 
energy consumption and energy expenditure and in-
dividual genetic sensibility to weight gain. Numerous 
epidemiological studies have reported that an excess 
of body weight is associated with a higher risk of de-
veloping a number of chronic diseases, such as type 2 
diabetes, cardiovascular disease and increased incidence 
of certain forms of cancer. Treatment or prevention of 
obesity is advised to reverse or avoid the onset of type 
2 diabetes and other obesity-related diseases, and the 
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current management of obesity is directed primarily to 
reduce energy intake and increase energy expenditure. 
Regulation of body weight and energy homeostasis is 
subject to complex regulatory mechanisms maintaining 
balance between energy intake, energy expenditure and 
energy stores.
There are a number of strategies that can be used to 
induce negative energy balance and weight loss, such 
as lifestyle modification including a reduction of en-
ergy intake, an increase in physical activity, a behavioral 
approach, and pharmacological or surgical treatment. 
Those strategies may result in significant weight loss 
in obese subjects, however the individual response is 
very variable. Existence of hypo or hyper responders 
supports the hypothesis that response to weight loss 
intervention is related to genetic variation and reliable 
predictors of successful weight loss are still not well un-
derstood. Weight loss is a complex trait that depends 
on many environmental, behavioral and genetic influ-
ences. The gene-environment interaction explains why 
some individuals are more prone to weight gain than 
others in a similar environment.
Genetic factors play an important role in weight 
regulation, since there are genes involved in regulation 
of energy expenditure, appetite, lipid metabolism, adi-
pogenesis, thermogenesis, cell differentiation. 
Association and linkage studies indicate links be-
tween candidate obesity genes and body weight, body 
mass index (BMI), body fat, fat distribution, energy 
expenditure, fuel oxidation and several other pheno-
typic characteristics of obesity, including obesity related 
health risks. More than 600 genes and chromosomal re-
gions have been reported to participate in body weight 
and energy metabolism regulation. Genes that have 
been associated or linked to human obesity are nume-
rous, whereas gene-environment interaction in relation 
to weight change has been studied less frequently.
The strong control of weight loss by genotype was 
confirmed by studies conducted in monozygotic twins 
(1). In addition to these, there are studies performed 
in unrelated subjects evaluating the effect of known ge-
netic polymorphisms on weight loss response after dif-
ferent types of interventions. One must not forget that 
the candidate genes variants that are associated with 
weight loss in obese people are often the same variants 
that were previously associated with obesity and weight 
gain. These associations among genetic groups might 
be confounded by differences in baseline measurements 
of obesity-related variables.
Most studies have focused on weight loss after a single 
intervention in a relatively homogeneous group where a sin-
gle or multiple genes were associated and where weight loss 
was not the primary focus of the study. A few studies were 
performed where weight loss intervention was primarily car-
ried out in different genotype groups matched by relevant 
obesity-related variables. Some studies also consisted in con-
trolled intervention trials with different treatment applied to 
two or more randomized groups, in which weight loss per 
genotype was not again the primary aim.
These studies relating weight loss interventions are 
difficult to compare and interpret because they show 
very heterogeneous populations (men, women, chil-
dren, obese, overweight, diabetic or pre-diabetic), 
heterogeneity in the duration and type of treatment 
(dietary, pharmacological, surgery), difference in the 
sample size, lack of adequate control groups, contra-
dictory apparent results, difficult to replicate and some 
possible non-publication of negative results.
Moreover, some groups reported synergetic effects 
of polymorphisms from different loci in the ability or 
resistance to weight loss therapies. All these interactions 
increase the complexity of prediction of a response to 
weight loss with genetic tests approach.
The purpose of this study was to provide an extensive 
overlook of current evidence, through literature review 
(2,3) on the role of the genetics on weight loss. This 
review for time and resource limitation is not an exten-
sive and systematic review. We studied the most plau-
sible candidate genes that are involved in energy balance 
pathways, body composition changes in response to diet 
or exercise interventions. We restricted our article to 
weight loss in excess weight population and didn’t focus 
on weight loss maintenance and weight regain. 
A summary of the genes candidates to influencing 
weight loss in weight loss strategies can be retrieve in 
Table 1.
GENES RElATED TO ENERGy ExpENDITURE 
Genes encoding proteins that are key regulators of 
energy balance are likely involved in modulation of 
body weight response to environmental changes. The 
change/adaptation of the metabolic rate after weight 
loss (reduction of fat-free mass) is described as being 
very variable with individuals: some will decrease and 
adapt to the new body size, others will decrease more 
and resist to weight loss. This inter-individual difference 
suggests genetic make-up effect.
Gene variants and effect on weight loss
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Table1. Selected genes candidates in influencing weight loss in weight loss strategies
Gene Polymorphism References first author (year) 
Genes related to energy expenditure
Adreno receptor ADRB3 (Trp64Arg) Shiwaku and cols. (5), Nakamura  and cols. (8), Yoshida and cols. (4), Lee and 
cols. (10) 
NegATive: Fumeron and cols. (6), Rawson and cols. (7), Kim and cols. (14); 
coNTRARY: Xinli and cols. (9)
Uncoupling proteins UCP1 (A-3826g) 
UCP2 (g-866A)
Shin and cols. (16), Yoon and cols. (17)
Genes related to appetite control
Leptin LEP (c-2549A) (5’-region) Mammès and cols. (18)
Leptin receptor LEPr  (Ser343Ser) (T/c) Mammès and cols. (19), de Luis Roman and cols. (20)
Pro-opiomelanocortin POMC (R236g) NegATive: Santoro and cols. 2006 (21)
Serotonin receptor HTR2C promoter (c-759T) Pooley and cols. (24)
Neuromedin beta NMB (Pro73Thr) Spálová and cols. (25)
Melanocortin receptor MC4R
MCR3R (c17A) (6241A)
NegATive: Hainerová and cols. (22)
Santoro and cols. (23)
Adipogenic genes
Peroxisome proliferator-activated receptor 
PPARg2
PPARg2 (Pro12Ala) Østergård and cols. (33); Adamo and cols. (29); Lindi and cols. (27); 
NegATive: Niklas and cols. (30), Aldhoon and cols. (31), Stefanski and cols. (32)
Genes related to insulin resistance
insulin receptor substrates/insulin-like growth 
factor
IRS1 (gly972Arg)/iRS-2 (g1057D)/  
IGF (gAA1013gAA) 
NegATive: Laukkanen and cols. (42)
insulin 2 Near INSIG2 (rs7566605) Reinehr and cols. (43)
Genes related to lipid metabolism
Apolipoproteins (apoenzyme) ApoE e4 & ApoB/vNTR Kee and cols. (34)
ApoA-IV-1/2 Lefevre and cols. (35); NegATive: Heilbronn and cols. (36)
APO A5 (T1131c) Aberle and cols. (37), Martin and cols. (38)
Hepatic lipase LIPC (g-250g) Todorova and cols. (39)
Perilipin PLIN (g11482A) corella and cols. (40); NegATive: Deram and cols. (41)
PLIN (A14995T) Deram and cols. (41)
Acyl-coA synthetase 5 ACSL5 (rs2419621) (c/T) Adamo and cols. (29)
Other genes potentially related to obesity and synergies 
Plasma factor vii Arg/gln353 NegATive: Pankow and cols. (45)
Angiotensin-converting enzyme ACE i/D NegATive: Kostis and cols. (46)
Fat mass and obesity associated FTO (rs9939609) NegATive: Müller and cols. (47)
ADRB3xIRS-1 Trp64Arg x gly972Arg Benecke and cols. (11)
CYP19/coMT (catechol-o-methyl-transferase) CYP19 11r/val108/158Met Tworoger and cols. (44)
ADRB3x UcP(1or3) (Trp64Arg) x (A-3826g) or (-55cÆT) Fogelholm and cols. (13), Kogure and cols. (12); NegATive: Kim and cols. (14)
Genes and drug treatment
Sibutramine
Serotonin transporter SLC6A4 (LS/SS) vazquez Roque and cols. (49)
g-protein beta 3 subunit GNB3 (c825T) Hauner and cols. (50)
Phenylethanolamine N-methyltransferase PNMT (g148A) Peters and cols. (51)
α2A adrenoreceptor c1291g, 5-HTTLPR, and 
gNα3 c825T genotypes
grudell and cols. (52)
Mazindol
Adrenoreceptor ADRB3 (Trp64Arg) Shimizu, Mori (53)
Genes and bariatric surgery
IL6 and UCP2 IL6 (g-174c), UCP2 (g-866A) Sesti and cols. (54); chen and cols. (55)
UCP1 UCP1 (A-3826g) NegATive: Luyckx and cols. (56)
g proteins GNAS1 (T393c), GNB3 (c825T) 
(g814A)
NegATive: Potoczna and cols. (57)
Gene variants and effect on weight loss
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Adrenergic receptor genes 
Adrenergic receptor genes (ADRB) play an important 
role in the adipocyte metabolism, mediating the rate of 
catecholamine-induced lipolysis. The adrenergic system 
plays a key role in regulating energy balance through 
thermogenesis and lipid metabolism.
For the ADRB3 Trp64Arg polymorphism (the most 
described), carriers of the Arg64 are more resistant to 
weight loss for homozygotes (4) or women carrying 
the allele (5). Other studies did not confirm this as-
sociation with weight loss studying various ADRB3 
polymorphisms (6,7), nevertheless a resistance to loose 
visceral fat was described in carriers of Arg64 confirmed 
by Nakamura and cols. (8). On the other hand, in 2001, 
Xinli and cols. described a better weight loss in children 
carriers of Arg64 (9).
An interesting study on Japanese women who com-
pleted 12-week lifestyle intervention linked the pres-
ence of 64Arg allele to resistance to weight loss, but 
this association disappeared after adjusting for the per-
centage change of energy intake (10).
Synergies between ADRB3 (Trp64Arg) and insulin 
receptor substrate IRS-1 (Gly972Arg), polymorphisms 
were described as resistant to weight loss for carriers of 
both less common alleles (11) in obese women after 13 
week intervention.
Synergies between ADRB3 and UCP1 were de-
scribed with a lower loss of weight when both polymor-
phisms were present (12,13). In 2004, Kim and cols. 
(14) studied synergies between ADRB3 and UCP3 on 
224 overweight-obese subjects who underwent a 12-
week mild weight reduction program (-300 kcal/day) 
and separated them in four categories per genotype of 
ADRB3 and UCP3. Despite similar weight reduction, 
they observed a higher abdominal adipose reduction in 
the wild type group and linked the presence of both 
variants to lower reduction.  They observed on a bene-
ficial effect of the weight loss program on wild type and 
that carriers of variant of ADRB3 were less beneficial.
ADRB2’s polymorphisms were most studied in 
weight loss maintenance and regain after two years, 
with a description of the Gly16 carriers being less able 
to maintain weight loss (15). 
Uncoupling proteins 
The uncoupling proteins (UCPs) are a family of car-
rier proteins located in the inner mitochondrial mem-
brane. Playing an important role in energy metabolism 
in cells, UCP polymorphisms were described as influ-
encing exercise efficiency, resting energy expenditure, 
substrate oxidation, energy metabolism, body weight 
change etc.
UCP-1 (A3826G) polymorphism was linked to 
lower weight loss response to a 25% reduction of ener-
gy intake (6). This group found that GG homozygotes 
were more resistant to weight loss. In Korean women, 
haplotypes of UCP1 ht3(GAG) was found to be linked 
to higher weight loss after one month of very low calo-
rie diet (VLCD) intervention (16). 
A recent study showed associations with weight 
loss after VLCD and haplotypes of ten polymorphisms 
(four of UCP2 and six of UCP3) (17) and concluded 
that UCP2-3 polymorphisms were good predictors of 
reduced body fat in response to VLCD.
GENES AND CONTROl Of AppETITE 
The regulation of food intake involves several genes 
and the mechanisms are coming clearer. Lately, much 
attention has been focused on the role of the hypotha-
lamic leptin-melanocortin system.
leptin 
Lower weight loss was described for the leptin (LEP) 
gene polymorphism in the promoter region 5’ (18) 
and for the carriers of the -2549A allele at position 
C-2549A, after low-calorie diet in obese women.
leptin receptor 
Two studies linked effect of polymorphism of leptin 
receptor (LERP) and weight loss: overweight women 
carrying the C allele of the Ser (T) 343 Ser (C) poly-
morphism lost more weight after low calorie diet than 
non-carriers (19), and the Lys656Asn was shown not 
to have influence in weight loss (20).
Melanocortin system genes 
Proopiomelanocortin (POMC) polymorphism R236G, 
even though linked with early onset obesity, showed no 
influence on the ability to loose weight in three chil-
dren heterozygous (21).
Mutations on MC4R, associated with intense feel-
ing of hunger and hyperphagia in childhood that de-
crease with aging, were described as not impacting abil-
ity to loose weight with a study evaluating influence on 
weight loss (22). 
Gene variants and effect on weight loss
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A clear gene-diet interaction between MC3R 
Thr6Lys and Val118Ile was recently described in the 
ability to lose weight (23) in obese children.
Serotonin receptor HTR 
Serotonin is involved in food intake regulation in the 
central nervous system (CNS). Heterozygous at the 
HTR2C (C759T) promoter is linked to more resistance 
to weight loss than homozygous CC or TT after weight 
loss program; some studies concluded that heterozy-
gosity impairs the ability to lose weight (24). 
Neuromedin beta 
Neuromedin beta (NMB) is a member of the bombe-
sin-like peptide family expressed in brain, gastrointes-
tinal tract, pancreas, adrenals and adipose tissue. The 
polymorphism (Pro73Thr) has been linked to higher 
disinhibition and more hunger and greater body fat 
accumulation, and was described as influent on the 
change in fat mass in the Québec Family Study (QFS). 
Recently, a study linked male T allele carriers of the 
(P73T) polymorphism to resistance to weight loss, but 
not in women (25).
ADIpOGENIC GENES
peroxisome proliferator-activated receptor (ppAR) 
These genes are involved in regulation of adipocyte 
growth and differentiation and were already associated 
with body weight control (26).
PPARG2 is a key transcription factor implicated 
in adipogenesis, glucose and lipid homeostasis. The 
polymorphism Pro12Ala was already linked positively 
to BMI and subjects with impaired glucose tolerance. 
Homozygotes for Ala12 allele were more successful in 
losing weight (27) in a three-year study and success in 
weight maintenance (28). Finally, a recent study (29) 
observed that this polymorphism was associated in 
obese women with diet resistance even after correction 
for baseline BMI. 
However, others studies (30) described no differences 
in weight loss for carriers of Ala12: a study of postmeno-
pausal obese women after six months of hypocaloric diet 
(they had a higher weight regain after 12 months follow-
up), another (31) in obese patients in a four-year period 
and also in obese with type 2 diabetes (32).
An interesting finding is that diet and exercise have 
opposite effects on weight loss in Ala12 carriers: they 
appear more resistant to diet-induced weight loss but 
more prone to loss on standard exercise training inter-
vention (33).
GENES Of THE lIpID METABOlISM
Apolipoproteins 
Kee and cols. (34) showed that subjects carrying variant 
of the Apolipoprotein E (apoE) e4 are more resistant 
to weight loss.
Apolipoprotein A (apoA-IV) was described to be in-
volved in the regulation of food intake and a study eval-
uating effect of polymorphism (T-1131C) on weight 
loss showed that C carriers are more prone to loose 
weight (35). On the other hand, another study (36) 
found no difference in weight loss. 
Apolipoprotein A5 (ApoA5) plays a role in triglycer-
ides metabolism, and the T-1131C polymorphism was 
found to be associated with weight loss after short-term 
dietary restriction in hyperlipaemic overweight men 
(37) with C carriers showing a higher BMI reduction, 
factor that was confirmed in another study, in which C 
carriers lost significantly more weight (38).
Hepatic lipase gene (lIpC) 
Subjects with the G-250A promoter polymorphism 
showed difference in weight loss, both in control and 
intervention groups (39). 
perilipins 
Perilipins (PLIN) are a family of proteins that coat 
the intracellular lipid droplet. They are key regulators 
of the lipolysis and triglycerides mobilization. Poly-
morphism (G11482A) was described as influencing 
weight loss during body weight reduction strategy of 
low-energy diet; obese patients carrying 11482A al-
lele were more resistant to weight loss after one year 
(40). This finding was not confirmed in obese chil-
dren after 20-week lifestyle intervention, although the 
metabolic syndrome risk was very high among carrier 
of 11482A allele. Interestingly, another PLIN SNP 
(A14995T) was associated with better weight loss re-
sponse to the intervention (41). The best response to 
weight loss was linked to homozygotes of G11482 
and 14995T alleles.
Gene variants and effect on weight loss
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Acyl CoA synthetase 5 (ACSl5) 
These ACSL genes catalyze the production of fatty 
acyl-CoAs, and a SNP rs2419621 (C/T) was linked to 
weight loss response to diet in obese women (29).
GENES Of THE INSUlIN pATHwAy 
No significant weight reduction was described to geno-
type in the Finnish Diabetes Prevention Study (DPS), a 
large study that observed the influence on several vari-
ants of genes related to insulin signaling pathway: insu-
lin gene, insulin-like growth factor 1 receptor (IGF1-
1R), insulin receptor substrate 1 and 2 (IRS-1 and 2) 
and more on a lifestyle intervention on overweight sub-
jects with impaired glucose tolerance (42). However, 
they suggested that lifestyle intervention was not suc-
cessful in subjects carrying IGF-1R, IRS-1 and IRS-2 
polymorphisms.
Another study described an influence on weight loss 
when analyzing synergies between carriers of the IRS-1 
(Gly972Arg) polymorphism and ADRB3 (11).
Recently, a study confirmed that children homozy-
gous CC for the SNP rs7566605 (10kb from the insu-
lin gene 2 (INSIG2)) are more resistant to weight loss 
after one-year lifestyle intervention (43).
OTHER GENES RElATED TO OBESITy 
In 2004, Tworoger and cols. (44) studied two genes 
and their synergies on weight loss after exercise in-
tervention: subclass 19 cytochrome P450 aromatase 
(CYP19) and catechol-O-methyl-transferase (COMT). 
CYP19 contains a tetranucleotide repeat polymor-
phism (TTTA), from which 11r allele was associated 
with a higher loss of BMI and total fat after exercise-
induced in post-menopausal women intervention. A 
smaller weight loss was observed in carriers of Met/
Met versus Val/Val genotype of COMT. The best 
weight loss was linked to carriers of CYP19 11r and 
COMT (Val/Val).
The plasma factor VII (Arg-Gln353) gene polymorphism 
was not linked with ability to loose weight in a six-month in-
tervention in moderately obese men and women (45).
The angiotensin-converting enzyme insertion-
deletion (ACE I/D) polymorphisms were not linked 
to weight loss on 86 elderly white overweight hyper-
tensive subjects, but DD carriers showed a significant 
decrease in blood pressure and therefore weight loss 
sensitivity (46).
Some very recent strong positive associations with 
genes like FTO and obesity were reported. A recent 
study did not observed influence on weight loss for the 
polymorphism (rs9939609) on intervention program 
for German obese children and adolescents (47).
GENES AffECTING RESpONSE TO DRUG 
TREATMENT Of OBESITy 
Studies on drug induced weight loss provide addi-
tional evidence that genotyping could be of relevance 
in predicting efficacy of antiobesity drugs for obesity 
treatment.
Sibutramine 
Sibutramine, a promising drug for treatment of obesity, 
inhibits noradrenaline and serotonin reuptake and also 
enhances satiety. However a very large variety of weight 
loss response has been described.
Serotonin transporter is encoded by the gene sol-
ute carrier family 6 (neurotransmitter transporter, sero-
tonin), member 4 (SLC6A4) with long(L) and short(S) 
alleles.
There is a higher risk of adolescent obesity in S car-
riers (48) and LS/SS genotype was associated with bet-
ter weight loss after treatment (49).
The Guanine nucleotide-binding protein (G-pro-
tein), beta-3 subunit (GNB3) polymorphism C825T 
was linked to difference in weight loss between control 
group and group with sibutramine (50) with a higher 
weight loss on carrier of T allele in the control group 
and a higher weight loss for the CC homozygotes when 
treated with Sibutramine.
Phenylethanolamine N-methyltransferase (PNMT) 
is an enzyme that acts in catecholamine metabolism and 
catalyses the conversion of norepinephrine to epineph-
rine. Obese women AA carriers of (G148A) had a bet-
ter weight loss after 3-month therapy (51) but not after 
6 months.
A recent study (52) evaluated overall weight loss ef-
fect of placebo vs. sibutramine treatment for 12 weeks 
on 181 overweight or obese individuals and linked sig-
nificant response to weight loss for the α2A adrenore-
ceptor C1291G, 5-HTTLPR, and GNβ3 C825T geno-
types. With an enhanced effect with both 5-HTTLPR 
LS/SS and GNβ3 TC/TT, as well as α2A CC with 
GNβ3 TC/TT.
Gene variants and effect on weight loss
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Mazindol 
ADRB3 carriers of the polymorphism (Trp64Arg) 
showed a resistance to weight loss (53) when treated 
with mazindol.
GENES INflUENCING RESpONSE TO BARIATRIC 
SURGERy 
Interleukin 6 (IL6) and UCP2 genes were linked to 
weight loss after laparoscopic gastric banding after six-
months follow-up (54). Carriers of the C allele of IL6 
G-174C polymorphism and carriers of the G allele of 
UCP2 G-866A were more resistant to loose weight.
Several polymorphism of UCP2 gene were studied 
and rs660339 (Ala55Val) was linked to greater weight 
loss after 12 and 24 months for morbidly obese patients 
who underwent laparoscopic adjustable gastric band-
ing, but this was not observed in the ones who under-
went laparoscopic mini-gastric by-pass (55).
UCP-1 polymorphisms A-3826G was not linked to 
weight loss after gastroplasty on morbidly obese sub-
jects (56) after three-year follow-up.
None of the G protein (GNB3, C825T, G814A and 
GNAS1 T393C) polymorphisms were linked to weight 
loss in a population of 304 obese people, who under-
went bariatric surgery (57).
COMpREHENSIvE MUlTI GENE STUDIES 
Some comprehensive studies on gene-nutrient inter-
action have been managed by the Nutrient-Gene In-
teractions in Human Obesity: Implications for Dietary 
Guidelines (Nugenob), some are about SNPs others 
about gene expression.
In 2006, Sørensen and cols. (58), in a study about 
weight loss, concentrated results from eight clinical 
centers in Europe (648 obese adults), about 26 obesity 
candidate genes and 42 SNPs in a ten-week weight loss 
intervention with low-fat or high-fat diets. The authors 
did not conclude on any major influence of one par-
ticular SNP. 
They studied the most frequent genes involved in 
energy balance regulation and suggested a possible 
modulation on weight loss of the following genes: pro-
hormone convertase subtilisin/kexin type 1 (PCSK1), 
WW domain containing adaptor with coiled-coil 
(WAC), 11-beta hydroxysteroid dehydrogenase type 1 
(HSD11B1), and tumor necrosis factor-alfa (TNFA) – 
and also possible link with haplotypes of the glutamic 
acid decarboxylase 2 (GAD2) and ectonucleotide py-
rophosphatase/phosphodiesterase 1 (ENPP1). The 
conclusion was that possibly more severe diet restric-
tion and more duration are required to reveal a possible 
gene-diet interaction in weight loss intervention.
In 2006, Ruaño and cols. (59) described a sig-
nificant association with some genes and weight loss 
during a 4 to 12-week low carbohydrate intervention 
(CHO 10% of the total energy intake) on 86 normal 
and overweight healthy adults. Genotyping of 27 SNPs 
were studied and four had statistically significant associ-
ation with weight loss: gastric lipase (LIPF, rs814628), 
hepatic glycogen synthase (GYS2) (rs2306179), cho-
lesteryl ester transfer protein (CETP) (rs5883) and 
galanin (GAL, rs694066).
CONClUSION 
This review summarizes the current findings on selec-
ted genes candidates and their possible role in influen-
cing weight loss in weight loss strategies. The weight 
loss response to dietary change or to strategies such as 
exercise, drugs or surgery, is highly complex and with 
large interindividual variability. The healthy state and 
prevention of excess weight should have more atten-
tion than the bathroom scale.
The real challenge during weight loss is the loss of 
fat mass, and it is unfortunately accompanied with loss 
of lean mass; another challenge is a good maintenance 
of weight loss. Failure to recognize the benefits of exer-
cise independent of weight loss masks opportunities to 
counsel and educate patients.
The variability of the response to intervention in 
the numerous interventional studies shows a lack of 
homogeneous data in order to be able to compare 
them: ethnicity, physical condition, age, lifestyle differ-
ences all are characteristics that combined with length 
of intervention, sample size make the replication of the 
studies published difficult. Caution is needed before 
applying these results to clinical practice. Future studies 
will have to be large in order to assess the effects of 
multiple polymorphisms, and will have to control for 
many factors other than diet.
We reported various contradicting results; for ex-
ample, in the children population, the results after 
weight loss intervention are not similar to those ob-
served in adult population (41) – they are even contra-
dictory (9). 
Gene variants and effect on weight loss
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This biais could be explained by a different meta-
bolic adaptation to excess weight in young obese, that 
are not yet in state of resistance to weight loss, but will 
develop it later in life.
We also reported that losing weight may be more 
effective for some genotypes than others; furthermore, 
interventions for weight loss with no apparent effect on 
weight will have a positive effect on weight will have a 
benefic effect on metabolic status and were shown to 
reduce cardiovascular risk factors (36,46). Some indivi-
duals will also be hyper responder to weight loss, but will 
not maintain the weight and, sometimes, the presence of 
hetrozygosity may impair the weight loss success (24).
More and more, the synergies in between genes are 
being studied and multiple “positive” genotypes can 
act synergically (44).
Finally, lifestyle factors, such as decrease in energy 
intake, might mask effect on weight loss (10).
We are still at the beginning of the nutrigenetics stu-
dies and this is not enough to start specific personalized 
nutritional recommendations based on genetic infor-
mation (60). At present, it is premature to recommend 
the use of genotyping in the design of therapeutic diets 
or drug treatment. However, such studies are very use-
ful in identifying the mechanisms by which individuals 
are successful in losing weight, maintain it and which 
treatment is the more appropriate. Studies on drug-
induced weight loss provide additional evidence that 
genotyping could be of relevance in predicting efficacy 
of anti-obesity drugs for obesity treatment.
It is possible that more severe energy restriction and 
more prolonged weight management program are re-
quired to reveal the role played by gene-diet interaction 
in weight loss programs. 
And, a question is raised up about the relation be-
tween excess weight and poorer healthy state, since a 
significant portion of obese individuals can achieve lon-
gevity without developing the morbidities associated to 
obesity. One hypothesis is that total body fat is not the 
sole source of health complications but the fat distri-
bution is more the determining metabolic risk of the 
individual. How healthy is it to lose weight for an indi-
vidual? Is losing too much weight, in a short period of 
time, health beneficial and more beneficial than losing 
gradually and maintaining weight loss? What is the toll 
of yo-yo weight loss on health?
Disclosure: No potential conflict of interest relevant to this article 
was reported.
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